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Abstract The role of microglial cells in the pathogenesis
ofAlzheimer’sdisease(AD)neurodegenerationisunknown.
Although several works suggest that chronic neuroinﬂam-
mation caused by activated microglia contributes to
neuroﬁbrillary degeneration, anti-inﬂammatory drugs do
not prevent or reverse neuronal tau pathology. This raises
the question if indeed microglial activation occurs in the
human brain at sites of neuroﬁbrillary degeneration. In view
of the recent work demonstrating presence of dystrophic
(senescent) microglia in aged human brain, the purpose of
this study was to investigate microglial cells in situ and at
high resolution in the immediate vicinity of tau-positive
structures in order to determine conclusively whether
degenerating neuronal structures are associated with acti-
vated or with dystrophic microglia. We used a newly
optimized immunohistochemical method for visualizing
microglial cells in human archival brain togetherwithBraak
staging of neuroﬁbrillary pathology to ascertain the mor-
phology of microglia in the vicinity of tau-positive
structures. We now report histopathological ﬁndings from
19 humans covering the spectrum from none to severe AD
pathology, including patients with Down’s syndrome,
showing that degenerating neuronal structures positive for
tau (neuropil threads, neuroﬁbrillary tangles, neuritic pla-
ques) are invariably colocalized with severely dystrophic
(fragmented) rather than with activated microglial cells.
Using Braak staging of Alzheimer neuropathology we
demonstrate that microglial dystrophy precedes the spread
of tau pathology. Deposits of amyloid-beta protein (Ab)
devoid of tau-positive structures were found to be colocal-
ized with non-activated, ramiﬁed microglia, suggesting that
Ab does not trigger microglial activation. Our ﬁndings also
indicate that when microglial activation does occur in the
absence of an identiﬁable acute central nervous system
insult, it is likely to be the result of systemic infectious
disease. The ﬁndings reported here strongly argue against
the hypothesis that neuroinﬂammatory changes contribute
to AD dementia. Instead, they offer an alternative hypoth-
esisofADpathogenesisthattakesintoconsideration:(1)the
notion that microglia are neuron-supporting cells and neu-
roprotective; (2) the fact that development of non-familial,
sporadic AD is inextricably linked to aging. They support
the idea that progressive, aging-related microglial degen-
eration and loss of microglial neuroprotection rather than
induction of microglial activation contributes to the onset of
sporadic Alzheimer’s disease. The results have far-reaching
implications in terms of reevaluating current treatment
approaches towards AD.
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Introduction
Microglia are ubiquitously distributed cells in the central
nervous system (CNS) and recognized to be involved in
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15, 18, 33, 34]. Following acute insults to the CNS, micro-
glial cells become activated and participate in the natural
wound healing response [22, 45]. Their role in the patho-
genesis of Alzheimer’s disease (AD) remains controversial,
as they have been implicated in both neuroprotective and
neurotoxic ways [11, 15, 45]. A potential involvement of
microglia is most often seen within the context of the
amyloid cascade hypothesis [16] where it is thought that
ﬁbrillar Ab deposits constitute a chronic inﬂammatory
stimulus triggering long-lasting microglial activation that
results in the production of substances with neurotoxic
activities, which contribute to the onset of neurodegenera-
tion [11, 28, 32]. There are, however, caveats associated
with the amyloid cascade/neuroinﬂammation theory of AD
perhaps most importantly the fact that clear beneﬁts of
non-steroidal anti-inﬂammatory drugs for delaying onset or
reversing cognitive dysfunction in Alzheimer’s patients
have not been demonstrated [2, 26]. A direct pathogenic
link between amyloid plaques and neurodegeneration also
continues to remain elusive, because Ab deposits and
neuroﬁbrillary tangles do not arise in the same anatomical
locations, and cognitive impairment does not correlate with
amyloid plaque load but with presence of neuroﬁbrillar
pathologyevident as tau-positive structures such as neuropil
threads, neuroﬁbrillary tangles, and neuritic plaques [4, 7,
13, 37]. Additionally, unequivocal identiﬁcation of acti-
vated microglia in human brain has been difﬁcult to achieve
since there is no single biomolecular marker for distin-
guishing activated cells from non-activated ones, and this
has been complicated further by the fact that many micro-
glial cells in the aged human brain are dystrophic showing
morphological features indicative of senescence and/or
degeneration rather than of activation, such as fragmented
cytoplasmic processes [44]. However, recognition of dys-
trophic microglia has provided a new perspective on the
potential involvement of microglia in aging-related neuro-
degenerative diseases, namely, that neurodegeneration may
be occurring secondarily to microglial senescence and
associated loss of microglial neuroprotection [43, 45]. This
microglial dysfunction hypothesis is worth considering
because it (1) is based on the premise that microglia, like
other glial cells, are basically neuron-supporting cells and
thus neuroprotective; (2) is compatible with the fact that the
incidence of AD increases inevitably with aging and
therefore considers primarily non-familial, sporadic forms
of the disease, which represent greater than 90% of all
cases. The goal of the current study was to investigate
directly the microglial dysfunction hypothesis by examin-
ing microglial cells in human brain at high resolution in the
immediate vicinity of tau-positive structures in hopes of
being able to determine conclusively whether degenerating
neuronal structures are associated with activated or with
dystrophic microglia. The implications of resolving this
issue are signiﬁcant because if indeed there were evidence
for microglial degeneration, understanding of AD patho-
genesis would be steered into a new direction that would
produce fundamentally different treatment approaches:
rather than treating AD patients with anti-inﬂammatory
drugs to deactivate microglia therapeutic strategies aimed at
preserving or enhancing microglial cell function could
prove to be more effective.
Materials and methods
All human brain samples for light microscopy were obtained
from the brain bank at the Institute for Clinical Neuroanat-
omy, University of Frankfurt(Table 1). Nopatient data other
than age, sex, and diagnosis were disclosed. All brains were
ﬁxed and stored by immersion in a 4% aqueous solution of
formaldehyde for variable lengths of time beginning at the
time of brain removal from the skull. Blocks containing the
temporal lobe were embedded in polyethylene glycol (PEG
Table 1 Age, sex and neuropathology of human cases studied
No. Age Sex Neuroﬁbrillary
changes
a
Amyloid
a Classiﬁcation
1 22 M 0 0 Non-pathological
controls 24 9 F0 0
37 0 F0 0
47 7 M 0 0
5 21 F I 0 Minimal tau pathology
6
b 49 F I 0
77 1 FI 0
88 8 FI 0
9 92 M II 0 Maximal tau pathology
without concurrent
amyloid
10 60 M V C Alzheimer’s disease
11 77 F V C
12 87 M V B
13 85 F VI C
14 52 F VI C Down’s syndrome
15 59 M VI C
16 43 M 0 B High amyloid burden
without concurrent
tau pathology
17 44 F 0 B
18 56 M 0 A
19 63 M 0 B
a Staging of neuropathology according to Braak and Braak [4];
amyloid stages: A, low density of deposits in isocortex with no
involvement of hippocampus; B, medium density of deposits in iso-
cortex with mild involvement of hippocampus; C, high density of
deposits in isocortex with mild involvement of hippocampus. All
cases were stage 0 synucleinopathies
b Subject died with sepsis
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1231000, Merck), and sections were cut on a macrotome at
100 lm inthe frontal plane atthe level ofthe uncus.Sections
were processed for immunohistochemical staining using
primary antibodies, ionized calcium binding adaptor mole-
cule 1 (iba1) (rabbit polyclonal, 1:1,000, Wako) for detecting
microglia, AT8 (mouse monoclonal, 1:2,000, Pierce Endo-
gen) for detecting human PHF-tau, and 4G8 (mouse
monoclonal, 1:4,000,Calbiochem) for detecting Ab. Primary
antibody binding sites were visualized using biotinylated
secondary anti-mouse or anti-rabbit antibodies made in goat
(Vector, 1:200) followed by streptavidin-peroxidase. Perox-
idase substrates were diaminobenzidine (DAB-H2O2)a n d
Vector SG substrate (Cat. No. SK-4700), to yield brown and
blue-gray reaction products, respectively. For double immu-
nohistochemical staining, the DAB substrate reaction was
alwaysperformedﬁrstandsectionswererinsedthoroughlyin
phosphate buffered saline, pH 7.2–7.4, before proceeding
with the second immunostaining reaction. Negative controls
consisted of omitting either the primary antibodies or incu-
bating primary antibodies with mismatched secondary
antibodies (e.g. primary mouse with biotinylated goat-anti-
rabbit). In addition to immunohistochemistry, Ab was visu-
alized also using the Campbell–Switzer advanced silver
technique and neuroﬁbrillary degeneration was shown using
the Gallyas technique, as described previously [5]. Prepara-
tions were examined and photographed using an Olympus
Vanox microscope, as well as a Zeiss Axioplan microscope
equippedwith differentialinterferenceoptics(Fig. 7).Three-
dimensional (3-D) reconstruction was performed using
analySIS Soft imaging system (Olympus).
Results
As a ﬁrst step in our investigation it was essential to have a
reliable histological method for demonstrating all microg-
lial cells in archival human brain specimens stored for
extended periods of time in formalin. To date no such
method has been described, and published procedures
demonstrate only partial visualization of microglial cells,
due to loss or masking of antibody binding sites as a result
of prolonged ﬁxation [27]. In initial screening studies using
100-lm-thick sections of formalin-ﬁxed human brains, we
found that an antibody against the iba1 [19] provided
excellent visualization of ramiﬁed microglia in normal,
non-diseased control subjects (Fig. 1). Unlike antibodies
against ferritin or HLA-DR antigens previously used for
staining microglia in human brain, anti-iba 1 worked
consistently well and labeled the entire microglial popu-
lation, as judged by the great density of cells revealed
throughout coronal sections of the temporal lobe (Fig. 1a,
b). No special pretreatment of sections for antigen
unmasking was required. Anti-iba1 staining also facilitated
differentiating between resting and activated microglia
using cell hypertrophy as the distinguishing feature
(Fig. 1c, d). Negative control sections with the primary
antibody omitted showed no staining at all. With this
method, we set out to ﬁrst study microglial morphology in
cases of Alzheimer’s disease showing the classic pathology
of senile plaques and neuroﬁbrillary tangles (Braak stages
V and VI, case nos. 10–13; Table 1). By combining anti-
iba1 staining with anti-tau immunolabeling (AT8 antibody)
Fig. 1 Anti-iba1
immunohistochemistry
produces speciﬁc staining of
microglia in archival human
brain tissue. a, b Low power
views demonstrate abundance
and even spacing of microglial
cells throughout the cortical
gray matter of the entorhinal
cortex in a non-pathological
control subject (case no. 3;
Table 1). Pial surface is on far
left in a. All cells show a non-
activated, non-dystrophic
morphology typical for normal,
resting microglia. c, d
Comparison of resting and
activated microglial
morphology in two age-matched
individuals (case nos. 2 and 6,
respectively). Activated
microglia (d) show cytoplasmic
hypertrophy in a subject with
sepsis. Scale bars 500 lm( a),
100 lm( b), 50 lm( c, d)
Acta Neuropathol (2009) 118:475–485 477
123we were able to generate clear representations of microglial
cells and degenerating neuronal structures (Fig. 2). The
extent of neurodegeneration was visible even to the naked
eye on AT8-stained coronal sections encompassing the
temporal lobe up to the middle temporal gyrus at the level
of the uncus. Microscopically, anti-tau immunolabeling, as
well as silver staining using the Gallyas method, promi-
nently highlighted neuroﬁbrillary tangles, neuritic plaques,
and neuropil threads, which were readily distinguished
from microglial cells in these double-stained preparations
(Fig. 2a–d). Negative controls with mismatched secondary
antibodies showed no staining at all. The visualization of
microglia with anti-iba1 failed to show any evidence of
microglial activation, such as hypertrophy of the cells’
processes or increased cell density due to proliferation.
However, clusters of microglia which have been described
consistently in the literature were abundant and always
associated with neuritic plaques. On high magniﬁcation,
the structure of microglial cells was strikingly abnormal in
that the cytoplasm of nearly all cells was fragmented into
many small pieces (Fig. 2). The use of 100-lm-thick sec-
tions allowed for 3-D analysis of microglial cell structure
by taking photomicrographs in multiple focal planes
(Fig. 2e) and then digitally reassembling the z-stack of four
or more images into a composite ﬁnal micrograph (Fig. 2f).
This type of 3-D reconstruction clearly established that
microglial fragmentation (cytorrhexis) was not due to
selective focusing but instead represented the actual mor-
phology of both clustered and surrounding cells. We
therefore concluded that neurodegenerative changes of AD
were associated not with microglial activation but with
microglial fragmentation, suggesting ongoing degenera-
tion. To further substantiate this idea we sought to
corroborate an association of microglial fragmentation
and tau pathology in other cases at extreme ends of the
spectrum of neuroﬁbrillary pathology, namely, in young
Fig. 2 Microglial
fragmentation is widespread in
Alzheimer’s disease brain and
colocalized with tau pathology.
Double-label
immunohistochemistry for
microglia (iba1) and tau (AT8)
in the entorhinal cortex (EC) of
case no. 12 (a–c). a Low power
view reveals tau-positive
neuritic plaques (black spots)i n
the cortical gray matter and
diffusely distributed neuropil
threads and tangles (lower
right); microglia (brown) are
evenly distributed throughout.
Higher magniﬁcation shows
neuroﬁbrillary tangle and
neuropil threads (b) and neuritic
plaque (c), which are
surrounded by fragmented
microglia lacking intact
morphology. d Ghost tangles in
the EC shown with silver
impregnation are surrounded by
microglial fragments. e–f iba 1
staining shows detail of
fragmented microglial cells in a
cluster (center) and in
surrounding cells. e Focus series
of individual micrographs taken
10–15 lm apart, reassembled
into composite image in f.
Scale bars 100 lm( a, b, e, f),
50 lm( c, d)
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123individuals with minimal tau pathology and in subjects
with Down’s syndrome (case nos. 5, 14, 15; Table 1) using
the same double-staining and 3-D reconstruction proce-
dures as for the AD cases. We were able to determine that
an area of minimal tau pathology in the hippocampus of a
young subject (case no. 5) was accompanied by selective
microglial cytorrhexis, whereas a non-pathological young
control subject (case no. 1) revealed intact ramiﬁed
microglial cells in the same brain region (Fig. 3). On the
opposite end of the spectrum were two cases of Down’s
syndrome both of which demonstrated widespread neuro-
ﬁbrillary and amyloid pathology virtually identical to the
most advanced forms of AD. As shown in Fig. 4, these
subjects revealed complete destruction and total loss of
microglial cell integrity to the point where hardly a single
intact microglial cell could be identiﬁed anywhere in the
section. Iba1-stained sections of both Down’s subjects
were littered with microglial debris consisting of numerous
cell fragments, spheroids, and severely atrophied and dis-
ﬁgured microglia. These ﬁndings clearly conﬁrmed our
notion that microglial degeneration and neurodegeneration
progress in synchrony.
To investigate the temporal relationship between micro-
glial deterioration and neuroﬁbrillary degeneration, we
took advantage of the predictability of the spread of tau
pathology inherent to Braak staging, namely, that neuro-
degeneration proceeds predictably from the allocortex
(entorhinal and hippocampal areas) to the isocortex [4]. By
performing simultaneous analysis of microglial morphol-
ogy in both the entorhinal cortex and middle temporal
gyrus in the same coronal section through the temporal
lobe at increasing Braak stages, we were able to determine
the extent of microglial dystrophy in regions already
showing neurodegeneration as well as in regions that
would have developed neurodegeneration if the subject had
lived longer. The results, shown in Fig. 5, demonstrate that
microglial cells begin their structural deterioration before
neuroﬁbrillary pathology sets in. This is particularly evi-
dent during Braak stage III where widespread microglial
cytorrhexis is coincident with extensive tau pathology in
Fig. 3 Microglial degeneration can occur independent of age and is
evident in cases of young subjects with minimal tau pathology.
Double-label immunohistochemistry for microglia (iba1) and tau
(AT8) is shown in the hippocampus of two young subjects with no (b)
or minimal (d) tau pathology (case nos. 1, 5). a, c Focus series of four
individual micrographs taken 10–15 lm apart, and reassembled into
composite images in b and d. Note the difference in microglial
morphology in the two young subjects, one of which shows minimal
tau pathology evident as neuropil threads (arrows in d). Microglia in
b show normal ramiﬁed appearance but are fragmented in d. Scale
bars 20 lm( a, c); 10 lm( b, d)
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123the entorhinal region but also present in the middle tem-
poral gyrus which does not yet show neurodegenerative
changes at this stage (Fig. 5g, h). These observations
strongly suggest that microglial degeneration precedes the
onset of neuroﬁbrillary pathology and therefore support
the hypothesis of a causal relationship between the loss
of microglial structural integrity and the onset of neuro-
degeneration.
Given the abundance of literature and seemingly over-
whelming evidence supporting a role of Ab in triggering
microglial activation [3, 43], we were compelled to
investigate the relationship between Ab and microglia in
situ using the microglial staining procedure employed in
this study. In order to do so in a ‘‘clean’’ manner (i.e.
without the possibly confounding presence of tau pathol-
ogy) we selected four subjects who had been diagnosed to
have substantial amyloid plaque load (case nos. 16–19;
Table 1) but were devoid of tau pathology, and performed
double-labeling histochemistry for microglia and Ab, the
latter being visualized using both immunological (antibody
4G8) and silver impregnation techniques (Fig. 6a, b). We
found remarkable consistency among these four subjects
in that none of them showed any evidence of microglial
activation and all were marked by the presence of fully
ramiﬁed, resting microglia showing even cell spacing
without clustering throughout the temporal lobe (Fig. 6a,
b). Indeed, it was impressive to observe how non-respon-
sive microglia were to these extensive Ab deposits which
occupied the full extent of cortical gray matter. There were
very few instances of dystrophic changes in these cells and
the microglial cytorrhexis seen so conspicuously in cases
with tau pathology was virtually non-existent. Findings
were identical regardless of whether Ab was demonstrated
with 4G8 immunohistochemistry or with the Campbell–
Switzer silver method supporting prior observations that
immunohistochemical and silver methods for staining
Ab yield near-identical results [5]. As a positive control
for purposes of demonstrating microglial activation, we
included one subject who was known to have died with
sepsis (case no. 6; Table 1). In this subject, microglial
activation was rampant and present throughout the full
extent of a temporal lobe section (Fig. 6c), yet despite this
fulminant neuroinﬂammation tau pathology was classiﬁed
as being a minimal Braak stage I, similar to other subjects
in this group (case nos. 5,7,8) that showed no neuroin-
ﬂammation. We interpret these ﬁndings to show that (1) Ab
does not cause microglial activation, and (2) microglial
activation does not cause or aggravate neuroﬁbrillary
degeneration.
Discussion
The current ﬁndings show that the neurodegenerative
changes that characterize AD are not accompanied by
microglial activation but instead by microglial dystrophy,
which likely reﬂects progressive degeneration of these cells
[44]. The signiﬁcance of these ﬁndings is that they provide
an explanation as to why anti-inﬂammatory drugs are
ineffective at preventing or diminishing neurodegeneration
and dementia. They serve to redirect thinking about AD
pathogenesis away from inﬂammation-induced damage and
towards an unexplored area of neuroscience, namely, pro-
cesses or events that can damage microglial cells. One such
process particularly relevant in the context of AD is
chronological aging, and it has become clear in the recent
years that microglia are subjected to aging-related changes,
including telomere shortening [9, 46]. Truncated telomeres
in peripheral blood leukocytes also have been identiﬁed as
a possible marker of increased dementia risk [14]. Since
microglia are essential for providing neuroprotection [45],
aging-related weakening of microglial neuroprotective
Fig. 4 Single-label (iba1) staining of microglia in two subjects with
Down’s syndrome (case nos. 14, 15) is shown in a and b, respectively.
Both micrographs reveal a total loss of microglial cell integrity and
show presence of microglial cell debris throughout; middle temporal
gyrus (a) and entorhinal cortex (b). Scale bar 50 lm
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123function is likely to have detrimental consequences for
neurons. We propose here that one such negative conse-
quence is development of neuroﬁbrillary pathology by
showing evidence that microglial degeneration likely pre-
cedes the onset of tau pathology.
How does one distinguish between resting, activated, and
dystrophic microglia? The most reliable way of determi-
nation is by a qualitative assessment of cell morphology,
which requires robust histochemical demonstration of the
cells in situ. The ﬁndings shown here are the results of
applying an optimal method for staining microglia inhuman
archival material using the iba1 antibody generated by Ito
et al. [19]. This method allows the demonstration of all
morphological subtypes of microglia, including resting,
activated and dystrophic cells which can be distinguished
readily based on morphological grounds alone (Fig. 7).
Thus, unlike prior studies we have not relied on purportedly
speciﬁc immunological markers for activated microglia,
such as major histocompatibility complex (MHC) antigens,
which have long been used to demonstrate ostensible
microglial activation (and thus neuroinﬂammation) in AD
and other neurodegenerative diseases [1, 29, 38]. Although
an upregulation of MHC antigens occurs on microglia
activated after acute injuries, as shown in numerous animal
studies, in human brain these antigens (HLA-DR) are
widely expressed by non-activated, ramiﬁed (resting)
microglia, as well as by dystrophic ones [10, 17, 27, 44],
and thus anti-MHC staining is a questionable method for the
identiﬁcation of activated microglia [6, 44]. Qualitative
morphological assessment also requires viewing microglia
at the highest magniﬁcation possible for light microscopy
and preferably in sections that measure at least 20 lmi n
thickness, which facilitates viewing in multiples focal
planes. Often human brain tissue is examined at low mag-
niﬁcation in thin sections of parafﬁn-embedded tissue, and
while this type of analysis may be sufﬁcient for making a
diagnosis it does not always afford the level of detail nec-
essary to distinguish between activated and dystrophic, or
Fig. 5 Microglial fragmentation precedes the spread of tau pathology
in the temporal lobe. Double-label immunohistochemistry for
microglia (iba1) and tau (AT8) is shown in three subjects with tau
pathology increasing from Braak stages 0–III (case nos. 3, 8, and 9).
Camera lucida drawings of the actual sections are shown in c, f, and i
indicating for orientation the uncus, as well as both sampling areas in
the EC and middle temporal gyrus (MTG); areas of tau pathology are
shaded in orange. Representative micrographs of the EC (a, d, g) and
MTG (b, e, h) reveal microglia (brown) and tau pathology (black)a t
the different stages. Normal ramiﬁed microglia are evident at stage 0
in both EC and MTG in the absence of tau pathology (a, b); mostly
fragmented microglia are seen in association with a neuroﬁbrillary
tangle and neuropil threads in d, whereas mostly ramiﬁed and only a
single fragmented cell (arrow) are present in e during stage I; severe
microglial fragmentation and loss of discernable cell shape is
colocalized with extensive tau pathology in g; microglial processes
are fragmented also in h in the absence of neurodegeneration, but
cells retain recognizable contours. Scale bar 50 lm( a, b, d, e, g, h)
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123between resting and dystrophic microglia. The recent
analysis by Sasaki et al. [40] claiming a close association
between activated microglia and tau pathology underscores
this point.
The principal feature of microglial dystrophy described
in this report is cytoplasmic fragmentation, or cytorrhexis, a
process that has not yet been studied in great depth. Cyto-
rrhexis appears to involve the pinching off or budding of
cytoplasmic fragments and this phenomenon bears some
resemblance to the cytoplasmic changes that occur during
apoptosis [20]. However, other prominent features of
apoptosis, notably nuclear fragmentation (karyorrhexis), are
not apparent during microglial cytorrhexis as the cells show
intact nuclei and nucleoli associated with fragmented pro-
cesses (e.g. Figs. 2, 7). Our previous work describing
microglial cytorrhexis in SOD1 transgenic rats also failed to
produce evidence in favor of microglial apoptosis [8], and
thus we are reluctant to categorize microglial cytorrhexis as
either apoptosis or as necrosis at this time. Additional
studies are needed to further characterize this seemingly
distinct mode of microglial degeneration involving pri-
marily cytoplasmic deterioration. Microglial cytorrhexis
occurs in the SOD1
G93A rat, a model of amyotrophic lateral
sclerosis [8]. Notably, in these animals which die at about
5–7 months of age due to motoneuron loss, the terminal
stages of their neurodegenerative condition are marked by
prominent microglial cytorrhexis in the spinal cord gray
matter where motoneurons are degenerating [8]. Although
the mode of motoneuron cell death in SOD1
G93A rats
remains enigmatic and does not appear to involve neuro-
ﬁbrillary pathology, this model provides an interesting
parallel to the current ﬁndings in that here too microglial
degeneration can be associated with neurodegeneration,
thereby supporting our hypothesis that neurodegeneration
may be secondary to microglial damage.
Although numerous reports have claimed a role for
amyloid peptides in activating microglia and possibly
stimulating phagocytosis by microglia (for reviews see [3,
43]), the current ﬁndings fail to corroborate the occurrence
of either microglial activation or phagocytosis in brains
marked by massive Ab loads. The fact that we did not
observe activated microglia in a spectrum of cases ranging
from none to severe AD pathology suggests that neither
soluble nor insoluble amyloid-beta proteins elicit micro-
glial activation. Since levels of soluble Ab have been
correlated with cognitive impairments [25, 31], our
observations do not support the suspected causality
between soluble Ab levels and impaired cognition from a
neuroinﬂammation point of view. However, it is possible
that soluble Ab contributes to microglial degeneration, and
this has been shown to occur in vitro under certain con-
ditions [21]. As for neuritic plaques, our ﬁndings clearly
Fig. 6 Microglial activation is absent in the presence of Ab but
extensive during sepsis. a Double-label immunohistochemistry for
microglia (iba1) and Ab (4G8) reveals fully ramiﬁed, non-activated
microglia evenly distributed throughout the EC gray matter in the
presence of extensive Ab deposits (case no. 17). Higher magniﬁcation
reveals full extent of microglial ramiﬁcation when Ab is visualized
using silver staining in the same subject (b). c Fully activated and
hypertrophic microglia are present throughout the EC gray and white
matter in a subject with sepsis (case no. 6). Inset Detail of microglial
hypertrophy typical for activated microglia. Scale bars 100 lm( a),
50 lm( b), 500 lm( c), 50 lm( inset)
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123show that these are accompanied by dystrophic microglia
(Fig. 2c), which needs an explanation for the many prior
observations reporting activated microglia associated with
these lesions [30, 35, 38, 39, 41]. One possibility may be
that in prior studies dystrophic microglia were misidenti-
ﬁed as activated microglia. This could have been due to
that antibodies used in earlier work produced incomplete
visualization of microglial cells and also because microg-
lial dystrophy had not yet been recognized. Another
possibility may be related to the dynamic structure of Ab
plaques, that is, as these deposits evolve and undergo
biochemical changes there may be a point where microglia
do become activated and then progress to become dystro-
phic concurrently with the onset of tau pathology. Yet a
third possibility is that the presence of systemic infectious
disease may have inﬂuenced prior assessments of microg-
lial activation and neuroinﬂammation in AD brain. Elderly,
demented patients often have systemic comorbidities, such
as pneumonia and other infections, and it has been shown
that infectious disease outside the CNS can profoundly
inﬂuence microglial activation [23, 27, 36]. Our ﬁndings
showing pervasive microglial activation in one subject who
died with sepsis (case no. 6) seem to conﬁrm this thought,
and they underscore the need for more discerning studies of
neuroinﬂammation that take into consideration the absence
or presence of peripheral infections.
In summary, the current ﬁndings offer an alternative
explanation for the involvement of microglia in AD path-
ogenesis, namely, that a loss of microglial cells contributes
to the onset of neurodegeneration. This possibility is
appealing because it takes into account old age as a pri-
mary factor in the pathogenesis of sporadic AD. According
to the microglial dysfunction hypothesis, both microglia
and neurons are subject to an aging-related decline in
functions and these are exacerbated by genetic and epige-
netic factors, including oxidative damage, which may be
particularly detrimental to microglia [24]. It remains
unclear at this time how exactly damage in microglia is
linked to tau pathology in neurons, but this may become a
fertile area of investigation in future research. Notwith-
standing this as of yet unexplored issue, it is worth noting
that in the recent years studies have begun to emerge which
Fig. 7 Shown are
representative examples of
dystrophic (a, b; case no. 9),
resting (c, d; case no. 3),
activated (e, f; case no. 6)
microglial cells at high power.
Each set of images shows the
same microscopic ﬁeld in two
focal planes using differential
interference optics. Dystrophic
cells are readily distinguished
from both resting and activated
cells by their fragmented
cytoplasmic processes.
Activated cells are distinguished
by their hypertrophy. Both
resting and activated cells have
continuous, non-fragmented
processes. All images are from
entorhinal cortex. Scale bar
20 lm
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123provide evidence for microglial abnormalities and degen-
eration in other neurodegenerative diseases, including
amyotrophic lateral sclerosis, Creutzfeldt–Jakob disease,
and Huntington’s disease [8, 42, 47], as well as in
schizophrenia [48]. Thus, breakdown of the brain’s
immune system may be an important factor in the devel-
opment of neurodegeneration.
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